not yet recruiting

Monitoring to the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA®

key information

study id #: NCT04159987

condition: Spinal Muscular Atrophy

status: Not yet recruiting


SPINRAZA® (Nusinersen) is the first intrathecal administered drug which was approved by the FDA to treat SMA children and adults (2016). The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen).

intervention: Spinraza intrathecal injection


last updated: February 04, 2022